Filing Details
- Accession Number:
- 0001209191-14-043671
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-06-25 20:30:23
- Reporting Period:
- 2014-06-23
- Filing Date:
- 2014-06-25
- Accepted Time:
- 2014-06-25 19:30:23
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1459266 | Zs Pharma Inc. | ZSPH | Pharmaceutical Preparations (2834) | 263305698 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1332034 | Marc Ostro | 508 Wrangler Drive, Suite 100 Coppell TX 75019 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-06-23 | 1,422,901 | $0.00 | 1,432,649 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2014-06-23 | 824,913 | $0.00 | 2,257,562 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2014-06-23 | 168,910 | $0.00 | 2,426,472 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2014-06-23 | 160,000 | $18.00 | 2,586,472 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnote |
No | 4 | C | Indirect | See Footnote |
No | 4 | C | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B Preferred Stock | Disposition | 2014-06-23 | 1,422,901 | $0.00 | 1,422,901 | $0.00 |
Common Stock | Series C Preferred Stock | Disposition | 2014-06-23 | 824,913 | $0.00 | 824,913 | $0.00 |
Common Stock | Series D Preferred Stock | Disposition | 2014-06-23 | 168,910 | $0.00 | 168,910 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 9,748 | Indirect | See Footnote |
Footnotes
- Devon Park Associates, L.P. is the holder of record of 9,748 shares of common stock of the Issuer ("Common Stock"). Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P., which is the general partner of Devon Park Bioventures, L.P. Messrs. Marc Ostro, Christopher Moller and Devang Kantesaria are the founding members and managing directors of Devon Park Associates, LLC. Each such founding member (the "Founding Member") may be deemed to have shared voting and investment power over the shares beneficially owned by Devon Park Associates, L.P. and Devon Park Associates, LLC as described above. Each Founding Member disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Founding Members are the beneficial owners of such securities for Section 16 or any other purpose.
- Devon Park Bioventures, L.P. is the holder of record of shares of Series B Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock reported herein ("Preferred Stock") and shares of Common Stock issued upon conversion of the Preferred Stock and the 160,000 shares of Common Stock purchased as reported by this Form 4. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P., which is the general partner of Devon Park Bioventures, L.P. The Founding Members are the managing directors of Devon Park Associates, LLC and each such Founding Member may be deemed to have shared voting and investment power over the shares beneficially owned by the funds as described above. Each Founding Member disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Founding Members are the beneficial owners of such securities for Section 16 or any other purpose.
- The shares of Preferred Stock were converted into shares of Common Stock on a 1-for-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.